Hannah Beattie

Title: The Innovations of Hannah Beattie

Introduction

Hannah Beattie is an accomplished inventor based in Montreal, Canada. She has made significant contributions to the field of genetics and pharmacology, particularly in relation to warfarin therapy. Her innovative work focuses on identifying genetic predictors that can help manage the risks associated with this common anticoagulant treatment.

Latest Patents

Hannah Beattie holds a patent for her invention titled "Genetic predictors of international normalized ratio (INR) fluctuation with warfarin therapy." This patent describes methods and kits designed to identify subjects who have genetic predispositions to abnormal INR fluctuations during warfarin therapy. The invention includes a method that tests subjects for the presence of predetermined genetic variations correlated with these fluctuations. When the testing indicates the presence of such variations, the subject is identified as having a predisposition to abnormal INR fluctuations. Additionally, the patent outlines a kit that includes a test for these genetic variations, along with an indicator to help identify subjects at risk.

Career Highlights

Hannah Beattie is affiliated with the Institut De Cardiologie De Montreal, where she continues to advance her research and innovations. Her work has garnered attention for its potential to improve patient outcomes in those undergoing warfarin therapy.

Collaborations

Hannah collaborates with her coworker, Marie-Pierre Dubé, who is also a prominent figure in the field. Together, they work on projects that aim to enhance the understanding of genetic factors influencing medication responses.

Conclusion

Hannah Beattie is a notable inventor whose work in genetic predictors for warfarin therapy represents a significant advancement in personalized medicine. Her contributions have the potential to improve patient safety and treatment efficacy.